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Background
Bendamustine is an attractive option for the management of both de novo and relapsed 
lymphomas. It is being increasingly used in the conditioning regimen for autologous stem 
cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. 
In this study, we aimed to determine the safety and efficacy of bendamustine in the con-
ditioning regimen for autologous SCT in refractory/relapsed lymphomas.
Methods
We designed a descriptive study to evaluate bendamustine in combination with etopo-
side, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT.
Results
Fourteen patients (median age, 28 yr) with Hodgkin’s lymphoma (HL) (N=8), 
non-Hodgkin’s lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise 
specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×106
CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet 
engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortal-
ity rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four 
patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III 
diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete 
response and partial response, respectively. The median follow-up was 5.5 months (15 
days‒19 mo). At the final follow-up, 7 patients (50%) were alive and in CR.
Conclusion
Our study showed that bendamustine is a potentially toxic agent in the conditioning regi-
men for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. 
Further studies are required to assess its safety and efficacy at reduced doses.
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INTRODUCTION
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lympho-
mas (NHL) are highly chemotherapy-sensitive tumors. 
However, there is a significant subset of patients who relapse 
or who never achieve complete remission. Second line sal-
vage chemotherapy has been shown to be very effective 
in patients with chemosensitive diseases with CR rates great-
er than 50%, as observed with aggressive second line chemo 
immunotherapy in relapsed diffuse large B cell lymphoma 
(DLBCL) [1, 2]. 
However, the prognosis is usually poor with conventional 
salvage regimens alone [3, 4]. High dose therapy (HDT) 
followed by stem cell rescue is the treatment of choice for 
patients with relapsed/refractory lymphoma. Philip et al. 
[5] demonstrated a statistically significant difference in 
5-year event-free survival (46% vs. 12%; P=0.001) and OS 
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(53% vs. 32%; P=0.038) for patients undergoing autologous 
stem cell transplantation (ASCT) and salvage chemotherapy, 
respectively. With improvement in supportive care and man-
agement of toxicity resulting from the conditioning regimen, 
the survival rates after ASCT are approaching 60% for B 
cell lymphomas [6] and 40–70% in patients with HL [7, 
8].
Carmustine, etoposide, and cytarabine with melphalan 
(BEAM) is the most common conditioning regimen used 
for ASCT for relapsed lymphoma. Other regimens that have 
been studied include cyclophosphamide (BEAC), cyclo-
phosphamide, carmustine, and etoposide (CBV), and cyclo-
phosphamide-TBI (total body irradiation), but BEAM re-
mains the preferred conditioning regimen [9, 10]. Recently, 
availability of carmustine has been problematic in certain 
parts of the world. Therefore, there is increasing interest 
in exploring other active agents that could potentially replace 
carmustine in the conditioning regimen for ASCT. 
Bendamustine is an attractive option to replace carmustine 
because it combines the alkylating activity of the nitrogen 
mustard group with the antimetabolite activity of the purine 
analog structure (benzimidazole ring). Given the uniqueness 
of its chemical structure, it has a different mechanism of 
action from traditional alkylating agents. Carmustine demon-
strates only partial cross-resistance (in vitro) with other alky-
lating agents. It leads to cell death via single and double 
strand DNA cross-linking, and has also been shown to acti-
vate apoptotic pathways [11]. Therefore, bendamustine has 
clinical potential for treating diseases that are refractory 
to alkylators. It has shown superior efficacy compared to 
standard therapies for relapsed chronic lymphocytic leuke-
mia and indolent NHL [12], and is considered a standard 
first line treatment for indolent B cell lymphoma [13]. These 
data make it an attractive option as part of the conditioning 
regimen in ASCT. 
Carmustine is not available in Pakistan. After encouraging 
results from a study by Visani et al. [14] demonstrating 
efficacy and manageable toxicity of cotreatment of bend-
amustine with etoposide, cytarabine, and melphalan, we have 
been exclusively using bendamustine, cytarabine, etoposide, 
and carmustine (BeEAM) as the conditioning regimen for 
ASCT to treat relapsed/refractory lymphoma at our 
institution. Here, we present the safety and efficacy data 
from use of the BeEAM protocol from the last 2 years.
MATERIALS AND METHODS
Patient population 
Fourteen patients with resistant/relapsed lymphomas, in-
cluding both NHL and HL, were included in this study. 
Patient files were retrospectively reviewed to collect data 
regarding their diseases, treatments, toxicities, and outcomes. 
This protocol was approved by the Ethical Review Committee 
of Aga Khan Hospital, Karachi.
Mobilization and conditioning regimen
Patients were mobilized with granulocyte colony stimulat-
ing factor (GCSF) (5 mg/kg, twice per day subcutaneously 
for 4 days) or cyclophosphamide. Patients that received cy-
clophosphamide (1.5 g/m2) then received GCSF (5 mg/kg, 
twice daily subcutaneously for 6 days). Patients that under-
went mobilization with GCSF alone underwent scheduled 
stem cell pheresis on day 4. For patients who received cyclo-
phosphamide and GCSF mobilization, stem cells were har-
vested on days 5 to 7 (depending on count recovery) using 
either a Cobe Spectra AutoPBSC or a COMTEC (Fresenius 
Kabi, Bad Homberg, Germany) system in the default software 
configuration recommended by the manufacturer. After stem 
cell collection, patients received the conditioning regimen, 
which consisted of bendamustine coupled with fixed doses 
of etoposide, cytarabine, and melphalan (BeAM) ad-
ministered in an inpatient setting. BeAM regimen was given 
per standard protocols and institutional guidelines. 
Hyperhydration was started on day -6, followed by bend-
amustine 150 mg/m2 (days -5 and -4), etoposide 150 mg/m2 
(days -5 to -2), cytarabine 150 mg/m2 (days -5 to -2), and 
melphalan 75 mg/m2 (day -1). Stem cell infusion was per-
formed on day 0. All patients received granulocyte colony 
stimulating factor (GCSF) from day +1. 
Supportive care and monitoring
A central line was inserted in all patients. They were 
admitted to a single room, and reverse barrier nursing was 
practiced. All patients were given antimicrobials (levofloxacin 
500 mg od or ciprofloxacin 500 mg bid), an antifungal (vor-
iconazole 200 mg qd), and an antiviral (valacyclovir 500 
mg bid) as prophylaxis starting at day -5. Blood tests were 
performed per standard protocols, and blood products were 
transfused to keep hemoglobin levels ＞8 g/dL and platelet 
count ＞15×109. In cases in which fever developed, patients 
were given intravenous broad-spectrum antibiotics. 
Piperacillin tazobactam or imipenem/meropenem were giv-
en for gram negative bacilli coverage. Vancomycin was the 
drug of choice for management of gram positive cocci. In 
addition, amphotericin B was used when fungal infections 
were suspected. Patient symptoms were assessed daily, and 
physical examinations were administered during their hospi-
tal stay and as per recommendations after follow-up.
Response criteria
Engraftment was defined as achievement of an absolute 
neutrophil count of 0.5×109 per liter for 3 consecutive days. 
Platelet engraftment was defined as a count of 20×109 per 
liter with transfusion independence. Patients were evaluated 
for response at 4 weeks after transplant, and then at day 
100, at the outpatient clinic. At subsequent follow-up visits, 
imaging was performed per the discretion of the treating 
physicians. All toxicities were defined using the National 
Cancer Institute’s Common Terminology Criteria for Adverse 
Events Version 3.0 (2003). All patients were evaluated using 
either computed tomography (CT) or positron emission to-
mography (PET) before and after ASCT.
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Table 1. Patient characteristics.
Characteristics N %
Age, median 14 28 yr
Sex
   Male 11 78.57
   Female 3 21.43
BMI, median 14 25.5
IPI
   0 3 21.4
   1 6 42.8
   2 2 14.2
   3 3 21.4
Diagnosis
   Hodgkin’s lymphoma 8 57.14
   Diffuse large B cell lymphoma 5 35.71
   PTCL NOS 1   7.14
Response to initial treatment
   CR 7 50.00
   Refractory 2 14.29
   Progressive 5 35.71
Response to relapse therapy 
   CR 8 57.14
   PD 1   7.14
   PR 5 35.71
No. of treatment prior to transplan
   2 11 78.57
   3 2 14.29
   4 1   7.14
Disease status at time of transplant
   CR 8 57.14
   PR 6 42.86
Abbreviations: CR, complete response; IPI, indicates international 
prognostic index; PD, progressive disease; PR, partial response; 
PTCL NOS, peripheral T-cell lymphoma, not otherwise specified.
Table 2. Nonhematological toxicity.
Adverse effect  Grade I-II  Grade III-V 
Electrolyte imbalances
   Hypokalemia    7 (50%)   7 (50%)
   Hypomagnesemia  10 (71.4%)   1 (7.1%)
Gastrointestinal toxicity
   Mucositis    5 (35.7%)   3 (21.4%) 
   Diarrhea    8 (57.1%)   5 (35.7%)
   Nausea/vomiting   7 (50%)   1 (7.1%)
   Abdominal pain   3 (21.4%)
   Upper GI bleed   2 (14.2%)
   Lower GI bleed   1 (7.1%)
Hepatotoxicity
   Increase transaminases   1 (7.1%)
   Increase ALP   4 (28.5%)
   Hyperbilirubinemia   4 (28.5%)   4 (28.5%)
Infectious complication
   Febrile neutropenia 13 (92.85%)
   Pneumonia   4 (28.5%)
   Septic shock   4 (28.5%)
   CMV infection   1 (7.1%)
Renal toxicity
   Acute kidney injury   5 (35.7%)   4 (28.5%)
Respiratory toxicity
   Pleural effusion   3 (21.4%)
   Respiratory failure   7 (50%)
Cardiotoxicity
   Elevated troponins   2 (14.2%)   2 (14.2%)
   Arrhythmia   1 (7.1%)
CNS toxicity 
   Seizures   1 (7.1%)   2 (14.2%)
Statistical analysis
The primary end point was to assess the safety and efficacy 
of bendamustine in the conditioning regimen for autologous 
stem cell transplantation in patients with relapsed/refractory 
lymphoma. The secondary objectives included assessment 
of time to progression and overall survival. Statistical analysis 
was performed in accordance with approved protocols. The 
Kaplan-Meier method was used to estimate overall survival. 
Data were analyzed using Strata 12.1 software. 
RESULTS
Patient characteristics
Patient characteristics are summarized in Table 1. 
Fourteen patients were included in this study. The median 
age of the included patients was 28 years (range, 16–58 yr). 
Eleven (78.5%) patients were males and three (21.43%) pa-
tients were females. Eight patients (57.14) had Hodgkin’s 
Lymphoma, five patients (35.71%) had Diffuse Large B cell 
Lymphoma, and one patient (7.14%) had peripheral T-cell 
lymphoma, not otherwise specified (PTCL NOS). DHAP/ 
RDHAP was the most commonly used regimen as a second 
line treatment (11 patients, 78.5%). Two patients (14.29%) 
received RICE/ICE. Eight patients (57.14%) were in CR at 
the time of transplant and six patients (42.86%) were in 
partial response.
Engraftment
The median number of CD34+ cells infused was 5.95×106 
cells per kilogram body weight (range, 3–17.2×106 cells per 
kg body weight). No engraftment failures were noted. The 
median number of days on GCSF was 24 (range, 13–40 days). 
The median time to neutrophil engraftment was 17 days 
(range, 14–29 days), and 24 days for platelet engraftment 
(range, 13–55 days) in our cohort. The average length of 
hospital stay was 20 days (range, 13–45 days). 
Non-hematological toxicity 
Electrolyte imbalances were a frequent complication in 
our patients. Serum potassium abnormalities were the most 
common with 7 patients (50%) experiencing grade III (GIII) 
hyperkalemia and 7 patients (50%) experiencing GI-II 
hypokalemia. Nine patients (64.28%) experienced gastro-
intestinal (GI) hypomagnesemia. Liver dysfunction was also 
a common side effect in our cohort. Eight patients (57.14%) 
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Fig. 1. Overall survival. Fig. 2. Disease free survival.
had mild hyperbilirubinemia and four (28.5%) patients expe-
rienced GIII-IV toxicity. Nine patients (64.29) had acute 
kidney injury, among which eight patients (57.14%) experi-
enced GII-III toxicity. Three patients (21.4%) had GIII-IV 
pleural effusion. Seven patients (50%) developed respiratory 
compromise requiring O2 and NIV support. Eight (57.14%) 
patients developed mucositis, of which five patients devel-
oped GI-II mucositis and three developed GIII mucositis. 
Gastrointestinal toxicity was seen in all of our patients. 
Twelve patients (85%) developed GII-III diarrhea during 
their hospital stays. Cardiotoxicity was also observed in our 
cohort. Four patients exhibited increased troponin, of which 
two patients had GIII toxicity, and one patient had GIV 
arrhythmia. 
Febrile neutropenia with GIII-IV severity was observed 
in 13 (92.86%) patients. Among these patients, nine had 
fever of unknown origin, one had a lower respiratory tract 
infection (LRTI), and one had both LRTI and Staphylococcus 
species associated CLABSI infection. One patient had septice-
mia secondary to Staph epidermidis and E coli. One patient 
had acinetobacter CMV pneumonitis as evidenced by trache-
al cultures. Transplant-related mortality at day 100 was 28% 
(Table 2).
Outcome analysis 
At the time of transplant, 8 patients (57.14%) were in 
complete metabolic response (CMR) whereas 6 patients 
(42.86%) were in PR. At day +100, 5 patients (37%) were 
in complete metabolic response on PET CT imaging, 3 (21%) 
patients showed partial response, and 2 patients (14%) had 
refractory disease. Transplant-related mortality at day 100 
was 28%. Among 8 patients who underwent ASCT in CMR, 
only 2 patients remained in CR and were alive at the final 
follow-up. Among 6 patients who had partial response to 
ASCT, 5 patients were in CMR at evaluation and were alive 
at the last follow-up.
Patients with a low to intermediate IPI score exhibited 
better response and survival compared to patients who had 
a high IPI score. Nine patients who had low or low to inter-
mediate IPI, 5 (55%) and one out of three patients (33.33%) 
with a high – intermediate IPI score patients in CMR at 
the last follow up. 
The median time to follow-up was 5.5 months (15 days 
to 19 mo). At the final follow-up, 5 patients had died. 
Infections and subsequent systemic complications, partic-
ularly septic shock and hospital acquired pneumonia, were 
the most common cause of death in our cohort. Other causes 
included meningoencephalitis and CMV pneumonitis. At 
the final follow-up (median time), 7 patients (50%) remained 
in complete response, 2 patients (14.3%) had relapsed, and 
5 patients (35.71%) had died. The median disease-free surviv-
al was 5.96 months (range, 0.46–27.96 mo) and the median 
overall survival was 5.42 months (range, 0.46–27.96 mo) 
(Figs. 1, 2). 
DISCUSSION
High-dose therapy followed by ASCT is the standard of 
care and the treatment of choice for eligible patients with 
chemosensitive, aggressive, relapsed NHL and HL. This treat-
ment has been validated by the PARMA and the CORAL 
studies, which demonstrated a significantly higher survival 
rate of greater than 50% after high-dose chemotherapy and 
autologous bone marrow transplantation than after conven-
tional chemotherapy [15]. Despite the improved survival 
rates provided by HDT/ASCT, applicability of this treatment 
to all relapsing patients is limited. Several factors impacted 
survival. Disease status is an important predictive factor for 
survival. Transplant-related morbidity and mortality is an-
other important determinant of outcome. 
The BEAM protocol has been the conditioning regimen 
of choice for ASCT since the initial report by Mills et al. 
[8] published in 1995. They reported that 5-year overall 
survival and progression-free survival rates were 41% and 
35%, respectively, with an early procedure-related mortality 
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rate of 7%. Over the years, improvement in patient selection, 
mobilization techniques, and supportive care has resulted 
in survival of greater than 70%, and TRM rates less than 
2% [16, 17]. A retrospective review published by Reid et 
al. [18] showed a trend toward better 3-year OS and PFS 
in response to an outpatient BEAM regimen compared to 
an inpatient BEAM regimen. This was also accompanied 
by a better toxicity profile. Furthermore mBEAM showed 
good tolerability, with the most frequently observed 
non-hematologic toxicity being oral mucositis, mainly of 
grade I/II (47%). This tolerability was better than the BEAM 
regimen [11] or variants such as FEAM5 and BeEAM [19].
Late toxicities, however, remain a serious concern. Studies 
have revealed that non-infectious interstitial pneumonitis 
resulting from BCNU-containing regimens was a serious 
complication, reported in 16–60% of the patients, with an 
associated mortality rate of 9% [8, 20]. BCNU-containing 
conditioning regimens have also been associated with an 
increased risk of non-relapse mortality when compared with 
other regimens [19-23]. Many regimens have been tested, 
and the BEAM regimen remains the standard of care despite 
its known serious side effects. 
Unavailability of carmustine in many parts of the world 
has led to efforts to develop a conditioning regimen without 
carmustine. Visani et al. [14] reported results of a Phase 
I/II study using increasing doses of bendamustine (160 mg/m2, 
180 mg/m2 and 200 mg/m2 given on day -7 and day -6) 
with fixed doses of etoposide, cytarabine, and melphalan 
(BeEAM regimen), administered as a preparative regimen 
for ASCT. Forty-three patients with resistant/relapsed HL 
(N=15) and NHL (N=28) were enrolled, with 9 in the phase 
I and 34 in the phase II studies. No patients experienced 
dose-limiting toxicity. TRM at day 100 was 0%. The fol-
low-up period at the time of publication was 18 months, 
with 81% of patients alive and disease-free at that time. 
Mucositis and GI toxicity were the most commonly observed 
side effects. No grade III/IV nephrotoxicity or cardiotoxicity 
was reported. These encouraging results led to further studies 
evaluating bendamustine as a component of the conditioning 
regimen. 
 In a large French multicenter study (Lysa group), bend-
amustine was administered at a median dose of 191 
mg/m2/day (range, 50–250 mg/m2/day) on days 6 and 7 with 
standard doses of etoposide, melphalan, and cytarabine. The 
results of this study highlighted early toxicities with bend-
amustine which may have been underrepresented in the 
Visani study due to small sample size. One hundred seven 
(28%) patients developed grade I-IV nephrotoxicity. Patients 
who developed ARF were also more likely to experience 
colitis, pneumonitis, cardiac arrhythmias, intensive care ad-
mission, and death. Multivariate analysis showed that crea-
tinine level at day 1, bendamustine dose ＞160 mg/m2, and 
age were independent prognostic factors for ARF. Ten per-
cent of patients needed intensive care management, and 
the toxic death rate was estimated at 5% [24]. Garciaz et 
al. [25] reported increased nephrotoxicity in response to 
BeAM in their patients. Nine (31%) patients developed early 
renal toxicity before the day of reinfusion, of which four 
(14%) patients experienced grade 3–4 renal impairment. At 
day 30, the cumulative incidence of nephrotoxicity was 48% 
(17% of grade 3–4), whereas in the BEAM cohort, renal 
impairment was only observed in 7% of patients (5% of 
grade 3–4, P＜0.001). As also noted by the Lysa group, pa-
tients who developed nephrotoxicity were more likely to 
need admission to the intensive care unit [24% of patients 
in the Lysa group vs. 10% of patients in the BEAM group 
(P=0.07)]. Cardiotoxicity was also more common in the 
BeAM group, with grade 2–3 cardiac toxicity observed in 
10% of patients (vs. 2% in the BEAM cohort, P=0.02). 
Our study showed a similar toxicity profile. Twenty-eight 
percent of our patients developed grade III-IV nephrotoxicity. 
In addition, we saw a higher incidence of grade II-IV colitis 
and hepatotoxicity than reported in previous studies. Septic 
shock and respiratory failure were observed in 28% and 
50% of patients, respectively. Four patients (28%) in our 
cohort died in the early transplant period as a result of 
septic shock and its complications. The cause of the higher 
incidence of toxic death compared to that in other similar 
studies is unclear and needs further examination. One hy-
pothesis is that higher doses of bendamustine were respon-
sible for increased toxicity. The Lysa group reported in-
creased toxicity at doses greater than 160 mg/m2. In our 
protocol, we used 150 mg/m2 of bendamustine at days 4 
and 5. Despite this dose reduction, we observed significant 
toxicities. Therefore, it is our opinion the appropriate dose 
and schedule of bendamustine requires further study. 
In conclusion, in our retrospective analysis, we reported 
a high incidence of renal and cardiac toxicity and an un-
usually high transplant-related mortality of 28% with bend-
amustine in the conditioning regimen for autologous stem 
cell transplant. Therefore, bendamustine should be used with 
caution. Prospective comparative studies are needed to con-
firm the appropriate dose and schedule of bendamustine, 
and to further evaluate the toxicities noted in retrospective 
studies before it is routinely adopted in clinical practice.
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